Belinostat trial for neuroendocrine cancer based on genetics
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called belinostat, possibly combined with other drugs, based on your genetic makeup. It aims to find the right dose for people with a rare and aggressive neuroendocrine cancer that started outside the lungs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of high-grade neuroendocrine cancer that started outside the lungs, and standard treatments are no longer working.
- You are 18 years or older.
- Your cancer can be seen on scans or lab tests (measurable or non-measurable disease).
- Your blood counts and organ function (kidney, liver, bone marrow) are within certain safe limits.
- You have not had certain chemotherapy, radiation, or experimental drugs within the last 2 weeks, and your cancer is not resistant to platinum-based chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted therapies (surufatinib and serplulimab) plus standard chemotherapy (platinum and etoposide) for people with a rare, aggressive type of cancer called neuroendocrine carcinoma that started outside the lung. The goal is to see if this new combination works better than chemotherapy alone.
This trial tests a combination of immunotherapy (benmelstobart), a targeted therapy (anlotinib), and chemotherapy as the first treatment for advanced neuroendocrine cancers that started in the lung or gut. It aims to see if this combo works better than standard chemo alone.
This trial tests a new drug, LBL-024, combined with standard chemotherapy (etoposide and platinum) for people with advanced neuroendocrine carcinoma. The goal is to see if this combination works better than chemo alone.
This trial tests a new drug (LBL-024) combined with standard chemo as a first treatment for a rare and fast-growing neuroendocrine cancer (EP-NEC) that started outside the lungs. It may offer a new option for people whose cancer has spread and who haven't had treatment yet.
This trial tests a new drug called Peluntamig (PT217) for people with certain types of neuroendocrine cancers, like small cell lung cancer. It aims to see if the drug can help when standard treatments stop working or aren't an option.
This trial looks at epigenomic markers in different types of neuroendocrine tumors and cancers to find better ways to diagnose and treat them. It may help if you have a neuroendocrine tumor or certain other gastrointestinal cancers that can be surgically removed or biopsied.
Hear when a new Neuroendocrine Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.